{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000066","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.487329+00:00","generated_at":"2026-05-18T09:05:54.380593+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance","bullets":["Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.","Nasdaq 20% issuance proposal passed, authorizing shares under December 2024 purchase agreement with C/M Capital Master Fund, LP.","Adjournment proposal passed but was not needed; quorum of 37.10% (789,213 of 2,127,286 shares) was present.","Reverse split vote: 561,364 for, 224,901 against; issuance vote: 124,631 for, 73,764 against (589,723 broker non-votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000066","json":"https://secwatch.observer/filing/0001615219-25-000066.json","markdown":"https://secwatch.observer/filing/0001615219-25-000066.md","text":"https://secwatch.observer/filing/0001615219-25-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/0001615219-25-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/flks-20250708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:05:54.380593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}